Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Preserved Left Ventricular Systolic Function

Next Previous
Trial Profile

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Preserved Left Ventricular Systolic Function

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms CHARM Preserved
  • Sponsors AstraZeneca

Most Recent Events

  • 06 Mar 2023 Results deriving individual patient data from 5 HFpEF trials (CHARM-Preserved, I-Preserve, TOPCAT (Americas), PARAGON-HF, and DELIVER; to study Geographical Variation in Patient Characteristics and Outcomes in Hfpef, presented at the 72nd Annual Scientific Session of the American College of Cardiology together with the World Heart Federation
  • 30 Mar 2020 Results (n=18244) of pooled analysis of PARADIGM-HF, PARAGON-HF, CHARM-Alternative and CHARM-Preserved assessing treatment benefits of S/V on total HF hospitalizations and CV death, presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology.
  • 28 Mar 2020 Results (n=18244) assessing putative placebo analysis of the effects of sacubitril/valsartan in heart failure patients in four studies (PARADIGM-HF, PARAGON-HF, CHARM-Alternative and CHARM-Preserved ) published in the European Heart Journal.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top